강직성 척추염(AS) : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Ankylosing Spondylitis (AS) Emerging Therapy and TPP Insights

Thelansis's "Ankylosing Spondylitis (AS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Ankylosing Spondylitis (AS) Overview

Ankylosing Spondylitis is a chronic, immune-mediated spondyloarthropathy strongly associated with the HLA-B27 gene, characterized by enthesitis, sacroiliitis, and progressive spinal fusion driven by severe TNF and IL-17 axis dysregulation. It manifests as insidious, inflammatory back pain and persistent morning stiffness that improves with physical activity. Extramusculoskeletal signs include acute anterior uveitis, extensive plaque psoriasis, and subclinical inflammatory bowel disease. Diagnosis combines clinical presentation, elevated acute-phase reactants, and sacroiliac joint inflammation caught on pelvic MRI. Severity and structural damage are quantified using validated ASDAS and BASDAI metrics. While oral NSAIDs remain the first-line symptomatic cornerstone, newly updated clinical guidelines enforce a specialized, treat-to-target strategy using advanced targeted therapies for refractory or erosive disease. Frontline biologics feature dual IL-17A and IL-17F inhibitors like bimekizumab and next-generation oral JAK inhibitors like upadacitinib. Importantly, management algorithms prioritize patient-specific comorbidities: for patients with concurrent active uveitis or severe structural bowel disease, monoclonal TNF inhibitors are heavily prioritized, whereas IL-17 blockers are strictly avoided in active intestinal flares. Supervised physical therapy and structured spinal mobility monitoring are mandated alongside these advanced biologics to limit long-term bony ankylosis, minimize elevated cardiovascular comorbidity risks, and maximize physical functional capacity.

Key Highlights

• In Germany, the diagnosed ankylosing spondylitis patient pool is projected to increase from approximately 202,963 in 2025 to 216,565 by 2035.
• Ankylosing spondylitis remains a chronic inflammatory disease causing progressive spinal damage and reduced mobility.
• Early diagnosis and treatment are essential to slowing structural progression and preserving physical function.
• Biologic therapies and targeted treatments have significantly improved disease outcomes.
• Persistent disease activity and delayed diagnosis continue to represent key clinical challenges.

Market Overview

• The Germany ankylosing spondylitis market is projected to grow from approximately $1.2 BN to $2.1 BN by 2035.
• Market growth is supported by:
• Increasing adoption of biologics and targeted therapies
• Growing awareness and earlier disease diagnosis
• Market value growth is driven by long-term treatment duration and premium therapeutic options.
• Future growth will depend on next-generation immunomodulatory therapies and personalized treatment strategies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Shenzhen Huishan Biotechnology Co., Ltd.
• Lynk Pharmaceuticals Co., Ltd.
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• SPH-BIOCAD (HK) Limited
• UCB Biopharma SRL
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• Akeso
• Janssen Research & Development, LLC
• Biocad
• Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
• Johnson & Johnson Private Limited
• AbbVie
• XBiotech, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)